Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers

08/02/16

- Data support CYC065 as potential treatment for chemotherapy-resistant, CCNE1-amplified, uterine serous carcinoma (USC); 90% of tumor samples overexpressed cyclin E1 (CCNE1) - BERKELEY HEIGHTS, N.J., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Read more

Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers 23.3 KB
Summary Toggle Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements

06/16/16

BERKELEY HEIGHTS, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
Read more

Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements 18.4 KB
Summary Toggle Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO

06/06/16

Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations

Read more

Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO 31.2 KB
Summary Toggle Cyclacel Announces Reverse Stock Split

05/27/16

BERKELEY HEIGHTS, N.J., May 27, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Announces Reverse Stock Split 20.3 KB
Summary Toggle Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

05/19/16

BERKELEY HEIGHTS, N.J., May 19, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of
Read more

Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19.9 KB
Summary Toggle Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

05/11/16

Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results 38.8 KB
Summary Toggle Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results

05/04/16

BERKELEY HEIGHTS, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results 19.1 KB
Summary Toggle Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors

04/18/16

Preclinical Data Presented at the AACR 2016 Meeting

Read more

Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors 391.4 KB
Summary Toggle Cyclacel Announces Receipt of Nasdaq Extension

04/11/16

BERKELEY HEIGHTS, N.J., April 11, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP); ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Announces Receipt of Nasdaq Extension 18.4 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results

03/24/16

-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT --

Read more

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 42.8 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results

03/17/16

BERKELEY HEIGHTS, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results 18.4 KB
Summary Toggle Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing

02/05/16

BERKELEY HEIGHTS, N.J., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market
Read more

Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing 17.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

02/02/16

BERKELEY HEIGHTS, N.J., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
Read more

Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference 17.9 KB
Summary Toggle Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016

01/11/16

Company to Present at the Biotech Showcase(TM) 2016 Conference

Read more

Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 28.7 KB
Summary Toggle Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium

12/14/15

Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium Berkeley Heights, NJ, December 14, 2015 - Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today
Read more

Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium 20.7 KB
Summary Toggle CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

11/23/15

In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting

Read more

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models 77.3 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

11/12/15

Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST

Read more

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results 39.9 KB
Summary Toggle Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference

11/09/15

CYC065 Predicted to be Effective in Leukemia and Triple Negative Breast Cancer

Read more

Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference 19.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results

11/05/15

BERKELEY HEIGHTS, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results 17.1 KB
Summary Toggle Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference

10/26/15

Mechanistic Rationale of CYC065 in Targeted Solid Tumors and Hematology

Read more

Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference 18.7 KB

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter